Page last updated: 2024-12-08

avasimibe

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID166558
CHEMBL ID101309
CHEBI ID177719
SCHEMBL ID15876
MeSH IDM0383476

Synonyms (69)

Synonym
BIDD:PXR0029
CHEBI:177719
[2,6-di(propan-2-yl)phenyl] n-[2-[2,4,6-tri(propan-2-yl)phenyl]acetyl]sulamate
avasimibe ,
ci-1011
166518-60-1
avasimibe (usan/inn)
D03012
benzeneacetamide, n-((2,6-bis(1-methylethyl)phenoxy)sulfonyl)-2,4,6-tris(1-methylethyl)-
((2,4,6-tris(1-methylethyl)phenyl)acetyl)sulfamic acid 2,6-bis(1-methylethyl)phenyl ester
n-((2,6-bis(1-methylethyl)phenoxy)sulfonyl)-2,4,6-tris(1-methylethyl)benzeneacetamide
n-((2,6-bis(1-methylethyl)phenoxy)sulfonyl)-2,4,6-tris(1-methylethyl)-benzeneacetamide
2,6-diisopropylphenyl ((2,4,6-triisopropylphenyl)acetyl)sulfamate
avasimibe [usan]
ci 1011
2,6-bis(1-methylethyl)phenyl ((2,4,6-tris(1-methylethyl)phenyl)acetyl)sulfamate
CHEMBL101309 ,
2,6-diisopropylphenyl 2-(2,4,6-triisopropylphenyl)acetylsulfamate
bdbm50069900
[2-(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-phenyl ester
[2,6-di(propan-2-yl)phenyl] n-[2-[2,4,6-tri(propan-2-yl)phenyl]acetyl]sulfamate
BCP9000344
avasimibe [usan:inn]
28lq20t5rc ,
pd 148515
unii-28lq20t5rc
ci1011
AVASIMIBE - CI-1011
avasimibe,ci-1011
NCGC00346572-01
AKOS015913985
avasimibe [inn]
avasimibe [mi]
avasimibe [who-dd]
S2187
n-[(2,6-diisopropylphenoxy)sulfonyl]-2-(2,4,6-triisopropylphenyl)acetamide
smr002530075
MLS006010991
MLS006010422
SCHEMBL15876
2,6-diisopropylphenyl (2-(2,4,6-triisopropylphenyl)acetyl)sulfamate
DTXSID80168117
mfcd00934956
J-523295
HY-13215
CS-5695
pd-148515
SR-01000944953-1
sr-01000944953
HMS3655H08
AS-74646
1-({[2,6-bis(propan-2-yl)phenoxy]sulfonyl}amino)-2-[2,4,6-tris(propan-2-yl)phenyl]ethan-1-one
avasimibe, >=98% (hplc)
NCGC00346572-02
2,6-diisopropylphenyl (2-(2,4,6-triisopropylphenyl)-acetyl)sulfamate
SW219628-1
avasimibe (ci-1011)
FT-0737704
EX-A2230
avasimibe; ci-1011; pd-148515
DB06442
BCP02302
SB19572
HMS3866C13
CCG-269706
sulfamic acid, n-[2-[2,4,6-tris(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl)phenyl ester
Q27254327
C73212
AC-35841

Research Excerpts

Overview

Avasimibe is an inhibitor of acetyl-CoA acetyltransferase-1 (ACAT1), and has been shown to enhance T lymphocyte cytotoxicity on tumor cells. It is currently under clinical development (phase III trials)

ExcerptReferenceRelevance
"Avasimibe is an inhibitor of acetyl-CoA acetyltransferase-1 (ACAT1), and has been shown to enhance T lymphocyte cytotoxicity on tumor cells."( Avasimibe can cooperate with a DC-targeting and integration-deficient lentivector to induce stronger HBV specific T cytotoxic response by regulating cholesterol metabolism.
Chen, X; Hu, W; Lv, M; Ma, S; Tang, Z; Zang, G; Zhang, Y, 2023
)
3.07
"Avasimibe is a novel orally bioavailable ACAT inhibitor, currently under clinical development (phase III trials). "( Pharmacology of the ACAT inhibitor avasimibe (CI-1011).
Alegret, M; Laguna, JC; Llaverías, G, 2003
)
2.04
"Avasimibe was found to be a substrate and inducer of hepatic CYP 3A, producing pronounced decreases in plasma drug concentrations subsequent to Day 1."( Preclinical safety evaluation of avasimibe in beagle dogs: an ACAT inhibitor with minimal adrenal effects.
Breider, MA; Milad, MA; Robertson, DG, 2001
)
1.31

Actions

ExcerptReferenceRelevance
"Avasimibe may modestly enhance the lipid-reducing effect of atorvastatin by further inhibiting the production of intracellular cholesterol through mechanisms that appear to be compatible in this population."( Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia.
Heinonen, T; Klepack, E; Lovalvo, J; Marais, AD; McLain, R; Raal, FJ, 2003
)
2.48

Treatment

Avasimibe treatment can also contribute to increase plaque stability, as it reduces the accumulation of lipids in the arterial wall. Avasimibes inhibits macrophage infiltration into the media and reduces matrix metalloproteinase expression and activity.

ExcerptReferenceRelevance
"Avasimibe treatment can also contribute to increase plaque stability, as it reduces the accumulation of lipids in the arterial wall, inhibits macrophage infiltration into the media and reduces matrix metalloproteinase expression and activity."( Pharmacology of the ACAT inhibitor avasimibe (CI-1011).
Alegret, M; Laguna, JC; Llaverías, G, 2003
)
1.32
"Treatment with avasimibe resulted in a 92% reduction of lesion area compared with the HC control group."( Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice.
de Wit, EC; Delsing, DJ; Gijbels, MJ; Havekes, LM; Jukema, JW; Offerman, EH; Princen, HM; van Der Boom, H; van Der Laarse, A; van Duyvenvoorde, W, 2001
)
0.91
"Treatment with avasimibe potently lowered plasma cholesterol levels in ApoE*3-Leiden mice and considerably reduced atherosclerotic lesion area in addition to its cholesterol-lowering effect. "( Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice.
de Wit, EC; Delsing, DJ; Gijbels, MJ; Havekes, LM; Jukema, JW; Offerman, EH; Princen, HM; van Der Boom, H; van Der Laarse, A; van Duyvenvoorde, W, 2001
)
0.92

Compound-Compound Interactions

ExcerptReferenceRelevance
" We studied the effects of a statin (atorvastatin) and its combination with an acyl-CoA:cholesterol O-acyltransferase (ACAT) inhibitor (avasimibe) on atherosclerotic regression and plaque stability as measured by matrix metalloproteinase 1 and 3 (MMP-1 and MMP-3) levels."( Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis.
Badimon, JJ; Chew, DP; Corti, R; Fallon, JT; Fayad, ZA; Fuster, V; Helft, G; Worthley, MI; Worthley, SG; Zaman, AG, 2007
)
0.54

Bioavailability

Avasimibe is a novel orally bioavailable ACAT inhibitor, currently under clinical development (phase III trials)

ExcerptReferenceRelevance
"An orally bioavailable acyl coenzyme A:cholesterol acyltransferase (ACAT) inhibitor, avasimibe (CI-1011), was used to test the hypothesis that inhibition of cholesterol esterification, in vivo, would reduce hepatic very low density (VLDL) apolipoprotein (apo) B secretion into plasma."( Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
Barrett, PH; Burnett, JR; Huff, MW; Kleinstiver, SJ; Newton, RS; Telford, DE; Wilcox, LJ, 1999
)
0.84
"Avasimibe is a novel orally bioavailable ACAT inhibitor, currently under clinical development (phase III trials)."( Pharmacology of the ACAT inhibitor avasimibe (CI-1011).
Alegret, M; Laguna, JC; Llaverías, G, 2003
)
2.04
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The relevance of this latter finding in only one dosage group is not known."( Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia.
Brown, AS; Davidson, MH; Davignon, J; Dujovne, CA; Heinonen, T; Insull, W; Keilson, LM; Koren, M; McLain, R; Schrott, H; Sprecher, D, 2001
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
monoterpenoidAny terpenoid derived from a monoterpene. The term includes compounds in which the C10 skeleton of the parent monoterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency4.15440.00529.466132.9993AID1347411
EWS/FLI fusion proteinHomo sapiens (human)Potency5.19860.001310.157742.8575AID1259252; AID1259253; AID1259255
Interferon betaHomo sapiens (human)Potency4.15440.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sterol O-acyltransferase 1Rattus norvegicus (Norway rat)IC50 (µMol)0.53450.00580.66266.0000AID1396706; AID437287
Sterol O-acyltransferase 2Homo sapiens (human)IC50 (µMol)9.20000.11003.20369.2000AID754941
Myc proto-oncogene proteinHomo sapiens (human)IC50 (µMol)63.88001.00005.73259.6700AID1777418
Sterol O-acyltransferase 1Homo sapiens (human)IC50 (µMol)5.92080.02501.79758.0000AID1396697; AID1396730; AID342634; AID392882; AID754942
Dual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)IC50 (µMol)63.88000.00254.38999.6700AID1777418
Sterol O-acyltransferase 1Mus musculus (house mouse)IC50 (µMol)0.47000.06000.59001.0000AID1396706; AID1396711; AID1396712
Acyl-CoA:cholesterol acyltransferase Oryctolagus cuniculus (rabbit)IC50 (µMol)7.60000.00600.98467.6000AID342637
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (96)

Processvia Protein(s)Taxonomy
cholesterol metabolic processSterol O-acyltransferase 2Homo sapiens (human)
macrophage derived foam cell differentiationSterol O-acyltransferase 2Homo sapiens (human)
cholesterol storageSterol O-acyltransferase 2Homo sapiens (human)
intestinal cholesterol absorptionSterol O-acyltransferase 2Homo sapiens (human)
cholesterol effluxSterol O-acyltransferase 2Homo sapiens (human)
very-low-density lipoprotein particle assemblySterol O-acyltransferase 2Homo sapiens (human)
low-density lipoprotein particle clearanceSterol O-acyltransferase 2Homo sapiens (human)
cholesterol homeostasisSterol O-acyltransferase 2Homo sapiens (human)
positive regulation of cell population proliferationMyc proto-oncogene proteinHomo sapiens (human)
regulation of gene expressionMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of gene expression via chromosomal CpG island methylationMyc proto-oncogene proteinHomo sapiens (human)
G1/S transition of mitotic cell cycleMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIMyc proto-oncogene proteinHomo sapiens (human)
MAPK cascadeMyc proto-oncogene proteinHomo sapiens (human)
branching involved in ureteric bud morphogenesisMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of mesenchymal cell proliferationMyc proto-oncogene proteinHomo sapiens (human)
chromatin remodelingMyc proto-oncogene proteinHomo sapiens (human)
intracellular iron ion homeostasisMyc proto-oncogene proteinHomo sapiens (human)
DNA damage responseMyc proto-oncogene proteinHomo sapiens (human)
response to xenobiotic stimulusMyc proto-oncogene proteinHomo sapiens (human)
response to gamma radiationMyc proto-oncogene proteinHomo sapiens (human)
regulation of cell cycle processMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of gene expressionMyc proto-oncogene proteinHomo sapiens (human)
regulation of telomere maintenanceMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of stress-activated MAPK cascadeMyc proto-oncogene proteinHomo sapiens (human)
protein-DNA complex disassemblyMyc proto-oncogene proteinHomo sapiens (human)
cellular response to UVMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of apoptotic processMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processMyc proto-oncogene proteinHomo sapiens (human)
fibroblast apoptotic processMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of monocyte differentiationMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of DNA-templated transcriptionMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of fibroblast proliferationMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of fibroblast proliferationMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of epithelial cell proliferationMyc proto-oncogene proteinHomo sapiens (human)
chromosome organizationMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of cell divisionMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of telomerase activityMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of transcription initiation by RNA polymerase IIMyc proto-oncogene proteinHomo sapiens (human)
ERK1 and ERK2 cascadeMyc proto-oncogene proteinHomo sapiens (human)
response to growth factorMyc proto-oncogene proteinHomo sapiens (human)
cellular response to hypoxiaMyc proto-oncogene proteinHomo sapiens (human)
cellular response to xenobiotic stimulusMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of metanephric cap mesenchymal cell proliferationMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway by p53 class mediatorMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of miRNA transcriptionMyc proto-oncogene proteinHomo sapiens (human)
regulation of somatic stem cell population maintenanceMyc proto-oncogene proteinHomo sapiens (human)
regulation of transcription by RNA polymerase IIMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of cell population proliferationMyc proto-oncogene proteinHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
cholesterol metabolic processSterol O-acyltransferase 1Homo sapiens (human)
cholesterol metabolic processSterol O-acyltransferase 1Homo sapiens (human)
macrophage derived foam cell differentiationSterol O-acyltransferase 1Homo sapiens (human)
cholesterol storageSterol O-acyltransferase 1Homo sapiens (human)
cholesterol effluxSterol O-acyltransferase 1Homo sapiens (human)
very-low-density lipoprotein particle assemblySterol O-acyltransferase 1Homo sapiens (human)
low-density lipoprotein particle clearanceSterol O-acyltransferase 1Homo sapiens (human)
cholesterol homeostasisSterol O-acyltransferase 1Homo sapiens (human)
positive regulation of amyloid precursor protein biosynthetic processSterol O-acyltransferase 1Homo sapiens (human)
regulation of cytokine productionDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
response to ischemiaDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
inflammatory responseDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
signal transductionDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
heart developmentDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
stress-activated protein kinase signaling cascadeDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
negative regulation of hippo signalingDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
p38MAPK cascadeDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
positive regulation of MAPK cascadeDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
positive regulation of protein kinase activityDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
positive regulation of DNA-templated transcriptionDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
cardiac muscle contractionDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
cellular response to lipopolysaccharideDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
cellular response to sorbitolDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
cellular senescenceDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
MAPK cascadeDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (29)

Processvia Protein(s)Taxonomy
fatty-acyl-CoA bindingSterol O-acyltransferase 2Homo sapiens (human)
sterol O-acyltransferase activitySterol O-acyltransferase 2Homo sapiens (human)
protein bindingSterol O-acyltransferase 2Homo sapiens (human)
cholesterol bindingSterol O-acyltransferase 2Homo sapiens (human)
acyltransferase activitySterol O-acyltransferase 2Homo sapiens (human)
cholesterol O-acyltransferase activitySterol O-acyltransferase 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingMyc proto-oncogene proteinHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificMyc proto-oncogene proteinHomo sapiens (human)
core promoter sequence-specific DNA bindingMyc proto-oncogene proteinHomo sapiens (human)
transcription coregulator bindingMyc proto-oncogene proteinHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificMyc proto-oncogene proteinHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificMyc proto-oncogene proteinHomo sapiens (human)
DNA bindingMyc proto-oncogene proteinHomo sapiens (human)
protein bindingMyc proto-oncogene proteinHomo sapiens (human)
identical protein bindingMyc proto-oncogene proteinHomo sapiens (human)
protein-containing complex bindingMyc proto-oncogene proteinHomo sapiens (human)
protein dimerization activityMyc proto-oncogene proteinHomo sapiens (human)
E-box bindingMyc proto-oncogene proteinHomo sapiens (human)
DNA-binding transcription factor bindingMyc proto-oncogene proteinHomo sapiens (human)
SCF ubiquitin ligase complex bindingMyc proto-oncogene proteinHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
fatty-acyl-CoA bindingSterol O-acyltransferase 1Homo sapiens (human)
sterol O-acyltransferase activitySterol O-acyltransferase 1Homo sapiens (human)
protein bindingSterol O-acyltransferase 1Homo sapiens (human)
cholesterol bindingSterol O-acyltransferase 1Homo sapiens (human)
cholesterol O-acyltransferase activitySterol O-acyltransferase 1Homo sapiens (human)
protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
MAP kinase kinase activityDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
protein tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
protein bindingDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
ATP bindingDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
protein kinase bindingDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
protein serine kinase activityDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
endoplasmic reticulumSterol O-acyltransferase 2Homo sapiens (human)
endoplasmic reticulum membraneSterol O-acyltransferase 2Homo sapiens (human)
brush borderSterol O-acyltransferase 2Homo sapiens (human)
endoplasmic reticulum membraneSterol O-acyltransferase 2Homo sapiens (human)
nucleusMyc proto-oncogene proteinHomo sapiens (human)
nucleoplasmMyc proto-oncogene proteinHomo sapiens (human)
nucleolusMyc proto-oncogene proteinHomo sapiens (human)
cytoplasmMyc proto-oncogene proteinHomo sapiens (human)
Myc-Max complexMyc proto-oncogene proteinHomo sapiens (human)
RNA polymerase II transcription repressor complexMyc proto-oncogene proteinHomo sapiens (human)
chromatinMyc proto-oncogene proteinHomo sapiens (human)
protein-containing complexMyc proto-oncogene proteinHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
endoplasmic reticulumSterol O-acyltransferase 1Homo sapiens (human)
endoplasmic reticulum membraneSterol O-acyltransferase 1Homo sapiens (human)
membraneSterol O-acyltransferase 1Homo sapiens (human)
endoplasmic reticulum membraneSterol O-acyltransferase 1Homo sapiens (human)
cytoplasmDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
nucleoplasmDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
cytosolDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
membraneDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (172)

Assay IDTitleYearJournalArticle
AID193516Evaluated for %change in cholesterol fed rats for non-HDL-C at the dose of 0.01 mg/kg determined by Chronic screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID189958Effect on the Cholesterol fed rats for total cholesterol level in rats at the dose of 1 mg/kg by Chroinc screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID437287Inhibition of ACAT in rat macrophages assessed as incorporation of extracellular [3H]-oleic acid-BSA complex into the intracellular cholesteryl ester after 24 hrs2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Synthesis and structure-activity relationships of N-(4-amino-2,6-diisopropylphenyl)-N'-(1,4-diarylpiperidine-4-yl)methylureas as anti-hyperlipidemic agents.
AID195946Effect on the Cholesterol fed rats for non-HDL-C in rats at the dose of 0.01 mg/kg by Chroinc screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID180071Effect on the Cholesterol fed rats for HDL-C in rats at the dose of 0.3 mg/kg by Chroinc screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID193503Evaluated for %change in cholesterol fed rats at the dose of 0.3 mg/kg determined by Acute screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID193513Evaluated for %change in cholesterol fed rats for HDL-C at the dose of 10 mg/kg determined by Chronic screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID1419375Antiatherosclerotic activity in Bio F1B hamster model of diet-induced atherosclerosis assessed as reduction in lipid accumulation areas in aortic arch at 0.3 to 10 mg/kg/day added to chow pellets by oil red O staining based assay relative to control2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Discovery of Clinical Candidate 2-(4-(2-((1 H-Benzo[ d]imidazol-2-yl)thio)ethyl)piperazin-1-yl)- N-(6-methyl-2,4-bis(methylthio)pyridin-3-yl)acetamide Hydrochloride [K-604], an Aqueous-Soluble Acyl-CoA:Cholesterol O-Acyltransferase-1 Inhibitor.
AID193661Evaluated for %change in cholesterol fed rats for total cholesterol at the dose of 0.1 mg/kg determined by Chronic screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID197702Effect on the plasma Cholesterol level in rats at the dose of 0.1 mg/kg by Acute screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID193521Evaluated for %change in cholesterol fed rats for non-HDL-C at the dose of 10 mg/kg determined by Chronic screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID167009Effect on Rabbits (Fed a Cholesterol-Free Casein Diet ) for plasma cholesterol at the dose of 1 mg/kg (pretreatment)1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID167012Effect on Rabbits (Fed a Cholesterol-Free Casein Diet ) for plasma cholesterol at the dose of 3 mg/kg (post treatment)1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID187226Effect on the Normal, Chow fed rats for Plasma total triglyceride level in rats at the dose of 3 mg/kg1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID1396725Toxicity in Bio F1B hamster model of diet-induced atherosclerosis assessed as reduction in total plasma cholesterol at 1 mg/kg/day added to chow pellets relative to control
AID195948Effect on the Cholesterol fed rats for non-HDL-C in rats at the dose of 0.1 mg/kg by Chroinc screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID193665Evaluated for %change in cholesterol fed rats for total cholesterol at the dose of 3 mg/kg determined by Chronic screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID187225Effect on the Normal, Chow fed rats for Plasma total triglyceride level in rats at the dose of 10 mg/kg1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID1396709Inhibition of ACAT1 in 1 mg/ml rat liver microsomes
AID1396727Toxicity in Bio F1B hamster model of diet-induced atherosclerosis assessed as reduction in total plasma cholesterol at 10 mg/kg/day added to chow pellets relative to control
AID189953Effect on the Cholesterol fed rats for total cholesterol level in rats at the dose of 0.001 mg/kg by Chroinc screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID193509Evaluated for %change in cholesterol fed rats for HDL-C at the dose of 0.03 mg/kg determined by Chronic screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID1396720Cmax in non-fasted Sprague-Dawley rat at 30 mg/kg, po by LC-MS/MS analysis
AID1396723Antiatherosclerotic activity in Bio F1B hamster model of diet-induced atherosclerosis assessed as reduction in lipid accumulation areas in aortic arch at 3 mg/kg/day added to chow pellets by oil red O staining based assay relative to control
AID193499Evaluated for %change in Normal, Chow fed rats for total cholesterol plasma level in rats at the dose of 10 mg/kg1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID193510Evaluated for %change in cholesterol fed rats for HDL-C at the dose of 0.1 mg/kg determined by Chronic screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID193664Evaluated for %change in cholesterol fed rats for total cholesterol at the dose of 10 mg/kg determined by Chronic screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID195951Effect on the Cholesterol fed rats for non-HDL-C in rats at the dose of 10 mg/kg by Chroinc screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID193524Evaluated for %change in cholesterol fed rats for total cholesterol at the dose of 0.01 mg/kg determined by Chronic screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID193500Evaluated for %change in Normal, Chow fed rats for total cholesterol plasma level in rats at the dose of 3 mg/kg1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID1396722Antiatherosclerotic activity in Bio F1B hamster model of diet-induced atherosclerosis assessed as reduction in lipid accumulation areas in aortic arch at 1 mg/kg/day added to chow pellets by oil red O staining based assay relative to control
AID197701Effect on the Normal, Chow fed rats for total cholesterol plasma level in rats at the dose of 30 mg/kg1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID193505Evaluated for %change in cholesterol fed rats at the dose of 10 mg/kg determined by Acute screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID193515Evaluated for %change in cholesterol fed rats for non-HDL-C at the dose of 0.001 mg/kg determined by Chronic screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID167010Effect on Rabbits (Fed a Cholesterol-Free Casein Diet ) for plasma cholesterol at the dose of 10 mg/kg (post treatment)1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID1419357Antiatherosclerotic activity in Bio F1B hamster model of diet-induced atherosclerosis assessed as reduction in CE to FC ratio in liver at 0.3 to 10 mg/kg/day added to chow pellets2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Discovery of Clinical Candidate 2-(4-(2-((1 H-Benzo[ d]imidazol-2-yl)thio)ethyl)piperazin-1-yl)- N-(6-methyl-2,4-bis(methylthio)pyridin-3-yl)acetamide Hydrochloride [K-604], an Aqueous-Soluble Acyl-CoA:Cholesterol O-Acyltransferase-1 Inhibitor.
AID1396706Inhibition of ACAT1 in mouse J774 cells assessed as reduction in esterified cholesterol accumulation after 18 hrs in presence of 25-hydroxycholesterol
AID180067Effect on the Cholesterol fed rats for HDL-C in rats at the dose of 0.001 mg/kg by Chroinc screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID197699Effect on the Normal, Chow fed rats for total cholesterol plasma level in rats at the dose of 10 mg/kg1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID193660Evaluated for %change in cholesterol fed rats for total cholesterol at the dose of 0.03 mg/kg determined by Chronic screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID1396697Inhibition of ACAT1 in human monocytes-derived macrophages reduction in cholesteryl oleate formation preincubated for 2 hrs followed by [14C]-oleic acid/BSA/sodium oleate addition measured after 2 hrs by TLC assay
AID189960Effect on the Cholesterol fed rats for total cholesterol level in rats at the dose of 3 mg/kg by Chroinc screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID1396702Inhibition of SOAT1 in arterial homogenates isolated from 1% cholesterol fed New Zealand white rabbit assessed as reduction in cholesteryl oleate formation incubated for 5 mins in presence of [14C]-oleoyl-CoA and BSA complex by TLC method
AID1396726Toxicity in Bio F1B hamster model of diet-induced atherosclerosis assessed as reduction in total plasma cholesterol at 3 mg/kg/day added to chow pellets relative to control
AID193496Evaluated for %change in Normal, Chow fed for rats Plasma total triglyceride plasma level in rats at the dose of 10 mg/kg1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID1396724Antiatherosclerotic activity in Bio F1B hamster model of diet-induced atherosclerosis assessed as reduction in lipid accumulation areas in aortic arch at 10 mg/kg/day added to chow pellets by oil red O staining based assay relative to control
AID1396729Antiatherosclerotic activity in Bio F1B hamster model of diet-induced atherosclerosis assessed as reduction in lipid accumulation areas in aortic arch at 0.3 mg/kg/day added to chow pellets by oil red O staining based assay
AID1396710Inhibition of ACAT1 in 0.2 mg/ml rat liver microsomes
AID193520Evaluated for %change in cholesterol fed rats for non-HDL-C at the dose of 1 mg/kg determined by Chronic screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID193518Evaluated for %change in cholesterol fed rats for non-HDL-C at the dose of 0.1 mg/kg determined by Chronic screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID193514Evaluated for %change in cholesterol fed rats for HDL-C at the dose of 3 mg/kg determined by Chronic screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID1396703Inhibition of SOAT2 in New Zealand white rabbit intestinal microsomes assessed as reduction in cholesteryl oleate formation incubated for 5 mins in presence of [14C]-oleoyl-CoA and BSA complex by TLC method
AID180068Effect on the Cholesterol fed rats for HDL-C in rats at the dose of 0.01 mg/kg by Chroinc screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID1396711Inhibition of ACAT1 in mouse IC21 cells in presence of BSA
AID437288Up-regulation of LDL receptor expression in human HepG2 cells at 100 nM by immunoblot analysis2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Synthesis and structure-activity relationships of N-(4-amino-2,6-diisopropylphenyl)-N'-(1,4-diarylpiperidine-4-yl)methylureas as anti-hyperlipidemic agents.
AID1777418Disruption of interaction between human recombinant GST-tagged MKK3/VF-tagged MYC expressed in HEK293T cells measured after 2 hrs by TR-FRET assay2021Bioorganic & medicinal chemistry, 09-01, Volume: 45Discovery of the first chemical tools to regulate MKK3-mediated MYC activation in cancer.
AID193662Evaluated for %change in cholesterol fed rats for total cholesterol at the dose of 0.3 mg/kg determined by Chronic screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID180069Effect on the Cholesterol fed rats for HDL-C in rats at the dose of 0.03 mg/kg by Chroinc screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID1419393Antiatherosclerotic activity in cholesterol fed F1B hamster model of diet-induced atherosclerosis assessed as reduction in lipid accumulation areas at 3 mg/kg2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Discovery of Clinical Candidate 2-(4-(2-((1 H-Benzo[ d]imidazol-2-yl)thio)ethyl)piperazin-1-yl)- N-(6-methyl-2,4-bis(methylthio)pyridin-3-yl)acetamide Hydrochloride [K-604], an Aqueous-Soluble Acyl-CoA:Cholesterol O-Acyltransferase-1 Inhibitor.
AID189956Effect on the Cholesterol fed rats for total cholesterol level in rats at the dose of 0.1 mg/kg by Chroinc screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID180073Effect on the Cholesterol fed rats for HDL-C in rats at the dose of 10 mg/kg by Chroinc screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID754941Inhibition of ACAT2 in human MDM assessed as inhibition of acetylated LDL-induced cholesterol ester accumulation after 1 hr by HPLC analysis2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Manzamine A, a marine-derived alkaloid, inhibits accumulation of cholesterol ester in macrophages and suppresses hyperlipidemia and atherosclerosis in vivo.
AID193502Evaluated for %change in cholesterol fed rats at the dose of 0.1 mg/kg determined by Acute screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID197703Effect on the plasma Cholesterol level in rats at the dose of 0.3 mg/kg by Acute screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID1396721AUC (0 to 8 hrs) in non-fasted Sprague-Dawley rat at 30 mg/kg, po by LC-MS/MS analysis
AID31057In vitro inhibition of ACAT by incubation with [1-14C]oleolyl-CoA and intestinal microsomes isolated from cholesterol-fed rabbits.1998Bioorganic & medicinal chemistry letters, Feb-03, Volume: 8, Issue:3
Inhibitors of acyl-CoA:cholesterol O-acyltransferase (ACAT) as hypocholesterolemic agents: synthesis and structure-activity relationships of novel series of sulfonamides, acylphosphonamides and acylphosphoramidates.
AID197704Effect on the plasma cholesterol level in rats at the dose of 1 mg/kg by Acute screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID197706Effect on the plasma cholesterol level in rats at the dose of 3 mg/kg by Acute screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID193522Evaluated for %change in cholesterol fed rats for non-HDL-C at the dose of 3 mg/kg determined by Chronic screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID195950Effect on the Cholesterol fed rats for non-HDL-C in rats at the dose of 1 mg/kg by Chroinc screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID197700Effect on the Normal, Chow fed rats for total cholesterol plasma level in rats at the dose of 3 mg/kg1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID180074Effect on the Cholesterol fed rats for HDL-C in rats at the dose of 3 mg/kg by Chroinc screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID193498Evaluated for %change in Normal, Chow fed for rats Plasma total triglyceride plasma level in rats at the dose of 30 mg/kg1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID193512Evaluated for %change in cholesterol fed rats for HDL-C at the dose of 1 mg/kg determined by Chronic screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID1419358Toxicity in Bio F1B hamster model of diet-induced atherosclerosis assessed as reduction in CE to FC ratio in adrenal gland at 0.3 to 10 mg/kg/day added to chow pellets2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Discovery of Clinical Candidate 2-(4-(2-((1 H-Benzo[ d]imidazol-2-yl)thio)ethyl)piperazin-1-yl)- N-(6-methyl-2,4-bis(methylthio)pyridin-3-yl)acetamide Hydrochloride [K-604], an Aqueous-Soluble Acyl-CoA:Cholesterol O-Acyltransferase-1 Inhibitor.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID193663Evaluated for %change in cholesterol fed rats for total cholesterol at the dose of 1 mg/kg determined by Chronic screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID342634Inhibition of ACAT-mediated esterified cholesterol accumulation in human THP1 cells exposed to acetyl-LDL during differentiation assessed as effect on foam cell formation2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Novel indoline-based acyl-CoA:cholesterol acyltransferase inhibitor with antiperoxidative activity: improvement of physicochemical properties and biological activities by introduction of carboxylic acid.
AID1480784Anti-hypercholesterolemic activity in poloxamer-407-induced Wistar rat lipoprotein lipase inhibition model assessed as fold change in triglyceride level at 20 mg/kg administered as single dose via oral gavage pretreated for 4 hrs followed by poloxamer-4072017European journal of medicinal chemistry, Apr-21, Volume: 130Vicinal diaryl azole-based urea derivatives as potential cholesterol lowering agents acting through inhibition of SOAT enzymes.
AID193523Evaluated for %change in cholesterol fed rats for total cholesterol at the dose of 0.001 mg/kg determined by Chronic screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID1396704Selectivity ratio of IC50 for inhibition of SOAT2 in New Zealand white rabbit intestinal microsomes to IC50 for inhibition of SOAT1 in arterial homogenates isolated from 1% cholesterol fed New Zealand white rabbit
AID193511Evaluated for %change in cholesterol fed rats for HDL-C at the dose of 0.3 mg/kg determined by Chronic screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID193497Evaluated for %change in Normal, Chow fed for rats Plasma total triglyceride plasma level in rats at the dose of 3 mg/kg1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID197705Effect on the plasma cholesterol level in rats at the dose of 10 mg/kg by Acute screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID194914In vivo percent change in plasma cholesterol level was measured at a dose of 30 mg/Kg in rat and expressed as deltaTC; p < 0.011998Bioorganic & medicinal chemistry letters, Feb-03, Volume: 8, Issue:3
Inhibitors of acyl-CoA:cholesterol O-acyltransferase (ACAT) as hypocholesterolemic agents: synthesis and structure-activity relationships of novel series of sulfonamides, acylphosphonamides and acylphosphoramidates.
AID1419378Antiatherosclerotic activity in Bio F1B hamster model of diet-induced atherosclerosis assessed as reduction in CE to FC ratio in intestine at 0.3 to 10 mg/kg/day added to chow pellets2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Discovery of Clinical Candidate 2-(4-(2-((1 H-Benzo[ d]imidazol-2-yl)thio)ethyl)piperazin-1-yl)- N-(6-methyl-2,4-bis(methylthio)pyridin-3-yl)acetamide Hydrochloride [K-604], an Aqueous-Soluble Acyl-CoA:Cholesterol O-Acyltransferase-1 Inhibitor.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID167008Effect on Rabbits (Fed a Cholesterol-Free Casein Diet ) for plasma cholesterol at the dose of 1 mg/kg (post treatment)1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID1396730Inhibition of ACAT1 in human monocytes-derived macrophages reduction in cholesteryl oleate formation preincubated for 2 hrs followed by [14C]-oleic acid/sodium oleate addition measured after 2 hrs in absence of albumin by TLC assay
AID193504Evaluated for %change in cholesterol fed rats at the dose of 1 mg/kg determined by Acute screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID1396712Inhibition of ACAT1 in mouse IC21 cells in absence of BSA
AID180070Effect on the Cholesterol fed rats for HDL-C in rats at the dose of 0.1 mg/kg by Chroinc screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID189954Effect on the Cholesterol fed rats for total cholesterol level in rats at the dose of 0.01 mg/kg by Chroinc screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID1396719Tmax in non-fasted Sprague-Dawley rat at 30 mg/kg, po by LC-MS/MS analysis
AID193508Evaluated for %change in cholesterol fed rats for HDL-C at the dose of 0.01 mg/kg determined by Chronic screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID392883Antihyperlipidemic activity in human HepG2 cells assessed as upregulation of hepatic LDL receptor expression at 100 nM2009Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4
Novel 1,4-diarylpiperidine-4-methylureas as anti-hyperlipidemic agents: dual effectors on acyl-CoA:cholesterol O-acyltransferase and low-density lipoprotein receptor expression.
AID189959Effect on the Cholesterol fed rats for total cholesterol level in rats at the dose of 10 mg/kg by Chroinc screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID167011Effect on Rabbits (Fed a Cholesterol-Free Casein Diet ) for plasma cholesterol at the dose of 10 mg/kg (pretreatment)1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID1419379Toxicity in rabbit2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Discovery of Clinical Candidate 2-(4-(2-((1 H-Benzo[ d]imidazol-2-yl)thio)ethyl)piperazin-1-yl)- N-(6-methyl-2,4-bis(methylthio)pyridin-3-yl)acetamide Hydrochloride [K-604], an Aqueous-Soluble Acyl-CoA:Cholesterol O-Acyltransferase-1 Inhibitor.
AID193517Evaluated for %change in cholesterol fed rats for non-HDL-C at the dose of 0.03 mg/kg determined by Chronic screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID193507Evaluated for %change in cholesterol fed rats for HDL-C at the dose of 0.001 mg/kg determined by Chronic screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID193519Evaluated for %change in cholesterol fed rats for non-HDL-C at the dose of 0.3 mg/kg determined by Chronic screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID180072Effect on the Cholesterol fed rats for HDL-C in rats at the dose of 1 mg/kg by Chroinc screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID193501Evaluated for %change in Normal, Chow fed rats for total cholesterol plasma level in rats at the dose of 30 mg/kg1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID754942Inhibition of ACAT1 in human MDM assessed as inhibition of acetylated LDL-induced cholesterol ester accumulation after 1 hr by HPLC analysis2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Manzamine A, a marine-derived alkaloid, inhibits accumulation of cholesterol ester in macrophages and suppresses hyperlipidemia and atherosclerosis in vivo.
AID189957Effect on the Cholesterol fed rats for total cholesterol level in rats at the dose of 0.3 mg/kg by Chroinc screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID195952Effect on the Cholesterol fed rats for non-HDL-C in rats at the dose of 3 mg/kg by Chroinc screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID195945Effect on the Cholesterol fed rats for non-HDL-C in rats at the dose of 0.001 mg/kg by Chroinc screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID195949Effect on the Cholesterol fed rats for non-HDL-C in rats at the dose of 0.3 mg/kg by Chroinc screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID193506Evaluated for %change in cholesterol fed rats at the dose of 3 mg/kg determined by Acute screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID195947Effect on the Cholesterol fed rats for non-HDL-C in rats at the dose of 0.03 mg/kg by Chroinc screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID342637Inhibition of normocholesterolemic rabbit liver ACAT2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Novel indoline-based acyl-CoA:cholesterol acyltransferase inhibitor with antiperoxidative activity: improvement of physicochemical properties and biological activities by introduction of carboxylic acid.
AID1419376Antiatherosclerotic activity in Bio F1B hamster model of diet-induced atherosclerosis assessed as reduction in total plasma cholesterol at 0.3 to 10 mg/kg/day added to chow pellets relative to control2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Discovery of Clinical Candidate 2-(4-(2-((1 H-Benzo[ d]imidazol-2-yl)thio)ethyl)piperazin-1-yl)- N-(6-methyl-2,4-bis(methylthio)pyridin-3-yl)acetamide Hydrochloride [K-604], an Aqueous-Soluble Acyl-CoA:Cholesterol O-Acyltransferase-1 Inhibitor.
AID1419395Antiatherosclerotic activity in cholesterol fed F1B hamster model of diet-induced atherosclerosis assessed as reduction in lipid accumulation areas at 30 mg/kg2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Discovery of Clinical Candidate 2-(4-(2-((1 H-Benzo[ d]imidazol-2-yl)thio)ethyl)piperazin-1-yl)- N-(6-methyl-2,4-bis(methylthio)pyridin-3-yl)acetamide Hydrochloride [K-604], an Aqueous-Soluble Acyl-CoA:Cholesterol O-Acyltransferase-1 Inhibitor.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID189955Effect on the Cholesterol fed rats for total cholesterol level in rats at the dose of 0.03 mg/kg by Chroinc screen test1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID1419394Antiatherosclerotic activity in cholesterol fed F1B hamster model of diet-induced atherosclerosis assessed as reduction in lipid accumulation areas at 10 mg/kg2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Discovery of Clinical Candidate 2-(4-(2-((1 H-Benzo[ d]imidazol-2-yl)thio)ethyl)piperazin-1-yl)- N-(6-methyl-2,4-bis(methylthio)pyridin-3-yl)acetamide Hydrochloride [K-604], an Aqueous-Soluble Acyl-CoA:Cholesterol O-Acyltransferase-1 Inhibitor.
AID187227Effect on the Normal, Chow fed rats for Plasma total triglyceride level in rats at the dose of 30 mg/kg1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID1777430Disruption of interaction between human recombinant GST-tagged MKK3/VF-tagged MYC expressed in HEK293T cells at 20 uM measured after 2 hrs by TR-FRET assay2021Bioorganic & medicinal chemistry, 09-01, Volume: 45Discovery of the first chemical tools to regulate MKK3-mediated MYC activation in cancer.
AID167013Effect on Rabbits (Fed a Cholesterol-Free Casein Diet ) for plasma cholesterol at the dose of 3 mg/kg (pretreatment)1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
AID392882Inhibition of ACAT in human HepG2 cells2009Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4
Novel 1,4-diarylpiperidine-4-methylureas as anti-hyperlipidemic agents: dual effectors on acyl-CoA:cholesterol O-acyltransferase and low-density lipoprotein receptor expression.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347164384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347172Secondary qRT-PCR qHTS assay for selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1347156DAPI mCherry counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347170Vero cells viability counterscreen for qRT-PCR qHTS assay of selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347158ZIKV-mCherry secondary qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347163384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347171Orthogonal mCherry assay for qRT-PCR qHTS of selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1347157Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (76)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's10 (13.16)18.2507
2000's31 (40.79)29.6817
2010's20 (26.32)24.3611
2020's15 (19.74)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.98 (24.57)
Research Supply Index4.43 (2.92)
Research Growth Index4.81 (4.65)
Search Engine Demand Index45.89 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (7.79%)5.53%
Reviews9 (11.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other62 (80.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]